* Alexion Pharmaceuticals Inc., of New Haven, Conn., filed ainvestigational new drug application with the FDA to begin clinicaltrials of a complement inhibitor for prevention of inflammationtriggered by use of a cardiopulmonary bypass machine during heartsurgery. The C5 Inhibitor 5G1.1-SC is Alexion's lead drug candidate.

* CV Therapeutics Inc., of Palo Alto, Calif., purchased NorthAmerican and European rights to develop and market ranzolazine, adrug under development for angina and ischemic heart disease. CVacquired the product candidate from Syntex U.S.A., of Palo Alto, asubsidiary of Roche Holdings Ltd., of Basel, Switzerland. Financialterms were not disclosed.

* Fujisawa Pharmaceutical Co. Ltd., of Osaka, Japan, made a $10million equity investment in PharMingen Inc., of San Diego.PharMingen makes and markets reagents for biomedical research andin vitro diagnostic products. Fujisawa, in July 1993, purchased rightsto sell PharMingen products in Japan.

* GelTex Pharmaceuticals Inc., of Waltham, Mass., registered for apublic offering of 2 million shares. Underwriters Cowen & Co. andHambrecht & Quist LLC, both of New York, have options topurchase an additional 300,000 shares to cover overallotments.GelTex, which went public in November 1995, develops non-absorbed, polymer-based drugs that selectively eliminate substancesfrom the gastrointestinal tract.

* Guilford Pharmaceuticals Inc., of Baltimore, which submitted anew drug application (NDA) in February 1996 for Gliadel, said theFDA accepted the NDA for review for brain cancer and the agencyexpanded the orphan drug status of Gliadel to include all forms ofmalignant glioma. Gliadel, a biodegradable wafer containingcarmustine, a chemotherapeutic drug, is implanted at the site of thecancer following surgical removal of the tumor.

* Organogenesis Inc., of Canton, Mass., entered into a researchagreement with Brigham and Women's Hospital, of Boston, forinvestigation of cell interactions related to formation of oral mucosaltissue. James Rheinwald, associate professor of dermatology atHarvard University in Cambridge, Mass., will conduct the research,which Organogensis believes may be applicable to periodontalsurgery.

* Techniclone International Corp., of Tustin, Calif., said its stock,previously traded on the Over-The-Counter bulletin board, is nowlisted on the NASDAQ market with the symbol, TCLN. Technicloneis developing monoclonal antibodies for drug delivery.

(c) 1997 American Health Consultants. All rights reserved.